NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Most of the current antidepressants for major depressive disorder (MDD) are based upon the
monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction
has been implicated in the pathophysiology of depression. This study aims to examine the
efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant
nonresponders with MDD.